vatalanib has been researched along with B16 Melanoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brueggen, J; Lane, HA; Littlewood-Evans, A; McSheehy, PM; O'Reilly, T; Schnell, C; Wood, JM | 1 |
| Åhgren, A; Hasumi, Y; Heldin, CH; Hellberg, C; Kłosowska-Wardęga, A | 1 |
| Allegrini, P; Brueggen, J; Cozens, R; Drevs, J; Guenther, C; Horsfield, M; Lebwohl, D; Lee, L; McSheehy, PM; Morgan, B; Schnell, C; Sharma, S; Steward, WP; Wood, J | 1 |
| Billy, E; Butler, J; Hla, T; LaMontagne, K; Liau, G; Littlewood-Evans, A; O'Reilly, T; Probst, B; Sanchez, T; Schnell, C; Theuer, A; Wood, A; Wood, J; Wyder, L | 1 |
| Furuhashi, M; Hasumi, Y; Heldin, CH; Hellberg, C; Kłosowska-Wardega, A; Ostman, A | 1 |
1 trial(s) available for vatalanib and B16 Melanoma
| Article | Year |
|---|---|
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with
Topics: Angiogenesis Inhibitors; Animals; Biomarkers; Colorectal Neoplasms; Dogs; Drug Evaluation, Preclinical; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats; Receptors, Vascular Endothelial Growth Factor | 2006 |
4 other study(ies) available for vatalanib and B16 Melanoma
| Article | Year |
|---|---|
Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Female; Mechanistic Target of Rapamycin Complex 1; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Models, Biological; Multiprotein Complexes; Neoplasm Metastasis; Phthalazines; Proteins; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Imatinib Mesylate; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Phthalazines; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-sis; Pyridines; Pyrimidines; RNA, Small Interfering; Signal Transduction | 2011 |
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
Topics: Animals; Calcium; Cell Growth Processes; Cell Movement; Cornea; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Melanoma, Experimental; Mice; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Phthalazines; Propylene Glycols; Pyridines; Receptors, Lysosphingolipid; Sphingosine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Imatinib Mesylate; Immunohistochemistry; Melanoma, Experimental; Mice; Pericytes; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |